The original success of the copyright undeniably revolutionized the drug landscape, but investing in companies heavily reliant on unbranded versions presents a challenging picture. While early profits were impressive, the expiration of patents and the rise of less expensive alternatives have diminished sales. Thus, a thorough assessment of current